Online inquiry

IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12068MR)

This product GTTS-WQ12068MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12068MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1654MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACT-017
GTTS-WQ9893MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ5538MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ4235MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ7993MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ9234MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ15327MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ889MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW